Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other ...

Diversification, especially including international holdings, is crucial for biotech investors to optimize portfolio performance amid market shifts. Despite broader industry weakness, quality ...

ZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.

An announcement from Moleculin Biotech ( ($MBRX) ) is now available. On May 23, 2025, Moleculin Biotech received a notification from Nasdaq ...

Performance data quoted represents past performance, which does not guarantee future results. Current performance may be lower or higher than the figures shown. Principal value and investment ...

Despite challenges, thematic and sector ETFs can have a meaningful role within an intelligently constructed portfolio.

Amgen AMGN and Bristol Myers Squibb BMY are among the largest global biotechnology companies with broad and diverse ...

The UK biotech was outperforming the broader market before COVID-19 hit and since then its relative performance has been stronger and there have been new investors entering the sector on the ...

A disconnect between upstream and downstream work continues to hold back progress in biomanufacturing, claims the CEO of ...

The industrial and energy segments saw a strong representation, with Inox Wind, PTC Industries, AstraZeneca Pharma, Inox Wind ...

The installation was finalized during Q1 2025 and supports critical pharmaceutical storage and cold chain logistics operations. This deployment represents the continuation of a multi-year relationship ...

ZURICH, May 20, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG ("VERAXA”), an emerging leader in ... company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH, "Voyager ...